Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.36 |
| ▸ | UMPS | P11172 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.34 |
| ▸ | ATG7 | O95352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14199831 | 1.00 | ADK (0.39) | ADKADORA3P2RY2P2RY14P2RY4 | |
| SCHEMBL6424353 | 0.84 | CDA (0.45) | — | |
| SCHEMBL14185075 | 0.82 | TDP1 (0.35) | P2RY2P2RY14P2RY4 | |
| SCHEMBL14185074 | 0.78 | PRKACA (0.33) | P2RY2P2RY4P2RY6 | |
| SCHEMBL14185071 | 0.78 | PRKACA (0.33) | P2RY2P2RY4P2RY6 | |
| SCHEMBL16199346 | 0.76 | CDA (0.40) | — | |
| SCHEMBL16198973 | 0.76 | CDA (0.40) | — | |
| SCHEMBL14185072 | 0.75 | SLC2A1 (0.33) | P2RY2P2RY6 | |
| SCHEMBL10024098 | 0.73 | CDA (0.48) | ADORA3 | |
| SCHEMBL17914216 | 0.73 | P2RY14 (0.53) | P2RY2P2RY14P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108557-A1 | Modified Proteins | PTMS, DNPEP, STT3A | ADK 4452/4885ADORA3 4860/4885P2RY2 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.